172 related articles for article (PubMed ID: 18815549)
41. Comparative analysis of microvessel density quantified through the immunohistochemistry expression of CD34 and CD105 in rectal cancer.
Goldiş DS; Sferdian MF; Tarţă C; Fulger LO; Totolici BD; Neamţu C
Rom J Morphol Embryol; 2015; 56(2):419-24. PubMed ID: 26193208
[TBL] [Abstract][Full Text] [Related]
42. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count.
Romani AA; Borghetti AF; Del Rio P; Sianesi M; Soliani P
J Surg Oncol; 2006 May; 93(6):446-55. PubMed ID: 16615157
[TBL] [Abstract][Full Text] [Related]
43. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium.
Breiteneder-Geleff S; Soleiman A; Kowalski H; Horvat R; Amann G; Kriehuber E; Diem K; Weninger W; Tschachler E; Alitalo K; Kerjaschki D
Am J Pathol; 1999 Feb; 154(2):385-94. PubMed ID: 10027397
[TBL] [Abstract][Full Text] [Related]
44. BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma.
Ratajczak P; Leboeuf C; Wang L; Brière J; Loisel-Ferreira I; Thiéblemont C; Zhao WL; Janin A
Mod Pathol; 2012 Jun; 25(6):805-14. PubMed ID: 22322190
[TBL] [Abstract][Full Text] [Related]
45. Endoglin (CD105) expression and angiogenesis status in small cell lung cancer.
Takase Y; Kai K; Masuda M; Akashi M; Tokunaga O
Pathol Res Pract; 2010 Nov; 206(11):725-30. PubMed ID: 20619547
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker.
Pizarro CB; Oliveira MC; Pereira-Lima JF; Leães CG; Kramer CK; Schuch T; Barbosa-Coutinho LM; Ferreira NP
Neuropathology; 2009 Feb; 29(1):40-4. PubMed ID: 18673444
[TBL] [Abstract][Full Text] [Related]
47. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
[TBL] [Abstract][Full Text] [Related]
48. Endoglin (CD105) expression in endometrial carcinoma.
Saad RS; Jasnosz KM; Tung MY; Silverman JF
Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
[TBL] [Abstract][Full Text] [Related]
49. Assessment of vascularity as an index of angiogenesis in periradicular granulomas. Comparison with oral carcinomas and normal tissue counterparts.
Davey KJ; Perrier S; Ohe G; Gilbert AD; Bankfalvi A; Saunders WP; Schor SL; Schor AM
Int Endod J; 2008 Nov; 41(11):987-96. PubMed ID: 19133088
[TBL] [Abstract][Full Text] [Related]
50. Endoglin (CD105) and claudin-5 expression in cutaneous angiosarcoma.
Hara H
Am J Dermatopathol; 2012 Oct; 34(7):779-82. PubMed ID: 23000880
[No Abstract] [Full Text] [Related]
51. Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors.
Kuiper P; Hawinkels LJ; de Jonge-Muller ES; Biemond I; Lamers CB; Verspaget HW
World J Gastroenterol; 2011 Jan; 17(2):219-25. PubMed ID: 21245995
[TBL] [Abstract][Full Text] [Related]
52. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
[TBL] [Abstract][Full Text] [Related]
53. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
El-Gohary YM; Silverman JF; Olson PR; Liu YL; Cohen JK; Miller R; Saad RS
Am J Clin Pathol; 2007 Apr; 127(4):572-9. PubMed ID: 17369132
[TBL] [Abstract][Full Text] [Related]
54. Is lymphatic endoglin expression a risk marker for breast cancer metastasis? Results of a pilot study.
Clasper S; Ogunbiyi SO; Baxter G; Turnbull L; Holt S
Lymphat Res Biol; 2013 Mar; 11(1):20-5. PubMed ID: 23531181
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma.
Kaira K; Sunose Y; Arakawa K; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Takeyoshi I
Histopathology; 2015 Jan; 66(2):234-43. PubMed ID: 24845232
[TBL] [Abstract][Full Text] [Related]
56. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas.
Couvelard A; O'Toole D; Leek R; Turley H; Sauvanet A; Degott C; Ruszniewski P; Belghiti J; Harris AL; Gatter K; Pezzella F
Histopathology; 2005 Jun; 46(6):668-76. PubMed ID: 15910598
[TBL] [Abstract][Full Text] [Related]
57. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
Behrem S; Zarkovic K; Eskinja N; Jonjic N
Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
[TBL] [Abstract][Full Text] [Related]
58. Expression of endoglin (CD105) in cervical cancer.
Zijlmans HJ; Fleuren GJ; Hazelbag S; Sier CF; Dreef EJ; Kenter GG; Gorter A
Br J Cancer; 2009 May; 100(10):1617-26. PubMed ID: 19352388
[TBL] [Abstract][Full Text] [Related]
59. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer.
Bono P; Wasenius VM; Heikkilä P; Lundin J; Jackson DG; Joensuu H
Clin Cancer Res; 2004 Nov; 10(21):7144-9. PubMed ID: 15534085
[TBL] [Abstract][Full Text] [Related]
60. Counting of angiogenesis in colorectal carcinomas using double immunostain.
Gurzu S; Cimpean AM; Kovacs J; Jung I
Tumori; 2012; 98(4):485-90. PubMed ID: 23052166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
